ABSTRACT
Background and Objective Patients with COPD have elevated levels of airway glucose. This may increase the risk of bacterial infection leading to exacerbation and disease progression. We aimed to test whether treating COPD patients with metformin, an oral hypoglycaemic used in diabetes, reduced airway glucose.
Methods In this randomized, double-blind, placebo-controlled crossover pilot study, we assigned patients with COPD to two 3-month periods of treatment with 1g metformin or placebo twice daily, followed by the alternate treatment after a 2-week washout period. Patients were required to be free of infection, antibiotic or oral steroid treatment in the 8 weeks prior to enrolment. The following were collected at baseline and monthly thereafter: sputum (lower airways sample), nasal/upper airway lining fluid samples using synthetic absorptive matrix (SAM), spirometry, and St Georges Respiratory Questionnaire (SGRQ) and COPD Assessment Test (CAT) scores. The primary outcome was a change in sputum glucose following 3 months treatment with metformin compared to 3 months of placebo.
Results 14 patients were randomised of whom 3 completed the study, mainly due to withdrawals for exacerbations (8/11 withdrawals). In the n=4 patients who completed 3 months metformin treatment, there were no significant changes in sputum or nasal glucose compared to baseline. Metformin did not affect COPD symptom scores or spirometry.
Conclusions Treatment with metformin in this underpowered pilot study did not significantly reduce airway glucose in COPD. Larger studies are required to definitively evaluate this.
SUMMARY AT A GLANCE Elevated airway glucose is associated with bacterial infection in chronic obstructive pulmonary disease (COPD) exacerbations. We tested whether metformin, a drug used to treat diabetes, reduced airway glucose in patients with COPD. Recruitment/retention difficulties led to an underpowered study, which observed no difference between metformin and placebo on airway glucose.
Competing Interest Statement
SLJ is a shareholder and Director of Virtus Respiratory Research Ltd.
Clinical Trial
NCT03651895
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Westminster Research and Ethics Committee
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
ClinicalTrials.gov Identifier: NCT03651895
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
